New Drug Development Status（As of November 8, 2024）
| Development Code | Planned Indication | Development Stage | Notes |
|---|---|---|---|
| KAR | Head lice | Phase Ⅲ | In-licensed from Arbor Pharmaceuticals, LLC. Product name in the US: Sklice |
| KP-001 | Refractory vascular malformations | Phase Ⅲ | Development project succeeded from ARTham Therapeutics Inc. |
| KC-8025 (Seladelpar) | Primary biliary cholangitis | Phase Ⅲ | In-licensed from CymaBay Therapeutics, Inc. Acquired by Gilead Sciences in February 2024. |
| KP-483 | Solid tumors (immuno-oncology) |
Phase Ⅰ | In-house discovered product |
| KP-910 | Peripheral neuropathic pain | Phase Ⅰ | In-house discovered product |
| Tildacerfont | Congenital adrenal hyperplasia | Phase Ⅰ | In-licensed from Spruce Biosciences, Inc. |
| KP-001(USA) | Refractory vascular malformations | Phase Ⅰ | Development project succeeded from ARTham Therapeutics Inc. |